Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 17/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847252 | 0.84 | GRIA4 (0.67) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL338199 | 0.84 | GRIA4 (0.67) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL3799849 | 0.84 | GRIA4 (0.67) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL6565117 | 0.75 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6847064 | 0.74 | GRIA4 (0.60) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL6847257 | 0.74 | GRIA4 (0.60) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL338200 | 0.74 | GRIA4 (0.60) | GRIA4CA1CA2GRIA2GRIA1 | |
| SCHEMBL13255761 | 0.70 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877671 | 0.70 | GRIA4 (0.73) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.70 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | FORMAN SCOTT LOUIS (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1330233-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002032389-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | GRIN2A, GRIN1, GRIN2B | GRIA4 14/4885CA1 1338/4885CA2 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.